Interventional Radiology Market

Interventional Radiology Market Analysis

The interventional radiology market size is valued at USD 28.55 billion in 2025 and is forecast to reach USD 38.03 billion by 2030, advancing at a 5.91% CAGR. Rapid migration from open surgery to minimally invasive, image-guided therapies underpins this expansion, reducing recovery times and lowering total expenditure for payers and providers. Artificial intelligence embedded in advanced imaging suites improves real-time guidance, elevates care quality, and stimulates procedure volumes in complex cardiovascular, oncologic, and neurovascular cases. Demand also benefits from a worldwide rise in chronic diseases that require repeat interventions and long-term disease management. At the same time, outpatient centers capture shifting procedure flows as pay-for-value reimbursement models reward cost-efficient care settings. Intensifying R&D investment from leading manufacturers sustains a strong pipeline of devices, software, and robotics that widen the addressable patient pool and open high-margin consumable revenue streams.

Key Report Takeaway

• By product, Imaging Systems led with 46.34% revenue share in 2024, while IR Consumables are projected to expand at a 7.45% CAGR through 2030.
• By procedure type, Diagnostic procedures accounted for 38.23% of the interventional radiology market share in 2024; Therapeutic procedures are advancing at a 7.66% CAGR to 2030.
• By application, Oncology captured 29.43% of revenue in 2024, whereas Urology & Nephrology is forecast to grow at an 8.23% CAGR through 2030.
• By end-user, Hospitals retained 57.98% of revenue in 2024, yet Office-Based Labs and Imaging Centers are expanding at an 8.54% CAGR to 2030.
• By geography, North America held 43.21% revenue share in 2024, while Asia-Pacific is set to grow the fastest at a 6.34% CAGR through 2030.

Global Interventional Radiology Market Trends and Insights

Rising Prevalence of Chronic and Lifestyle Diseases

Cardiovascular and oncologic burdens elevate demand for catheter-based interventions that offer durable clinical benefits. Transcatheter aortic valve replacement alone generated nearly USD 7 billion in 2024, signaling sustained procedure uptake. Neurovascular advances such as Terumo’s WEB system achieved an 86.5% occlusion rate for ruptured aneurysms, broadening indications previously treated via open craniotomy. Peripheral artery disease therapies progress with Abbott’s FDA-cleared Esprit BTK dissolving stent, designed for more than 20 million affected Americans. As life expectancy rises, chronic comorbidities generate steady procedural pipelines, anchoring long-term growth for the interventional radiology market.

Continuous Advancements in Minimally Invasive Imaging Technologies

Artificial intelligence reduces fluoroscopy times and radiation dose, exemplified by Siemens Healthineers’ Ciartic Move, which accelerates spine and pelvic procedures by up to 50%. Robotics integrated with AI enable leadless left bundle branch pacing, first performed with Abbott’s investigational conduction system pacing platform. RapidAI’s Lumina 3D reconstructs high-quality neuro images within minutes, addressing technologist shortages and supporting time-sensitive stroke workflows. Philips deepens innovation capacity through a multi-year collaboration with NVIDIA to develop MRI foundational models that deliver zero-click scan planning. Together, these developments raise procedural accuracy and create defensible differentiation for premium imaging suites.

Expansion of Interventional Radiology Applications Across Therapeutic Areas

Radiofrequency and microwave ablation reduce the need for thyroid surgery, providing image-guided alternatives with low complication rates. Clinical trials such as GENESIS II validate genicular artery embolization for knee osteoarthritis, opening new pain-management pathways. Liver ablation boundaries widen through IntelliBlate microwave systems that display real-time ablation zones, lowering collateral tissue. The U.S. FDA’s new radiological acquisition guidance lowers regulatory friction, accelerating market entry for novel devices. This diversification enables physicians to address a wider spectrum of diseases, lifting utilization rates across the interventional radiology market.

Shift Toward Outpatient and Day-Case Treatment Settings

Cerebral angiography performed in outpatient endovascular centers validates a shift pioneered by interventional cardiology. Private-equity-backed imaging chains expand geographically, increasing patient access and optimizing cost structures through high-throughput facilities. Consumer preferences favor convenient sites, boosting outpatient imaging’s share from 40% in 2024 to 46% within three years. Integrated health campuses that co-locate imaging with primary care streamline referrals and shorten care cycles. These changes redistribute revenue across care settings and amplify demand for mobile, compact imaging platforms suited to office-based labs.

High Capital and Operating Costs of Hybrid Imaging Suites

Hybrid suites blending angiography, CT, and MRI can exceed several million USD and require specialized shielding, HVAC upgrades, and multi-modal software integration. Ongoing service contracts and staff training raise the total cost of ownership and deter adoption in budget-constrained hospitals. Siemens Healthineers mitigates these barriers through decade-long Value Partnerships that amortize modernization costs and standardize equipment fleets. Nonetheless, small facilities often pursue mergers to access financing and pooled procurement, slowing diffusion in less-developed health systems.

Stringent Radiation Safety Regulations and Compliance Burdens

The FDA’s amended Quality System Regulation harmonizes with ISO 13485, requiring device makers to align documentation, traceability, and risk management by February 2026^{[1]U.S. Food and Drug Administration, “Quality System Regulation Amendments,” fda.gov}. Healthcare providers must also invest in dosimetry programs and periodic equipment audits, raising operational costs and prolonging facility upgrades. Although these rules enhance patient safety, they lengthen commercialization timelines and favor incumbents with established compliance infrastructures, restraining new-entrant momentum within the interventional radiology market.

Segment Analysis

By Product: Consumables Drive Revenue Despite Imaging Dominance

In 2024, Imaging Systems retained a 46.34% share, underscoring their foundational role in procedure planning and guidance. Continuous feature upgrades—such as AI-trained bone-removal algorithms on Siemens’ syngo DynaCT—support recurrent capital replacement cycles even as budgets tighten. IR Consumables, however, exhibit a 7.45% CAGR through 2030, reflecting their recurring revenue advantage as case volumes climb. Single-use catheters and embolization coils reduce cross-contamination risks and streamline inventory control, making them attractive for outpatient labs where turnover is high. The interventional radiology market size for consumables is projected to broaden swiftly as therapeutic complexity rises.

Accessories and workflow software outpace hardware growth because cloud analytics lower modality downtime and optimize scheduling. Philips’ helium-free BlueSeal MRI saves nearly 40 MWh annually per unit, illustrating how eco-efficiency complements clinical performance. Fluoroscopy systems that bundle AI-enabled dose monitoring meet tightening safety mandates and appeal to mid-tier hospitals. Overall, mature imaging infrastructure sets the stage for high-margin disposable uptake, driving profitable expansion across the interventional radiology market.

By Procedure Type: Therapeutic Growth Outpaces Diagnostic Foundation

Therapeutic procedures are advancing at a 7.66% CAGR, propelled by device breakthroughs like Merit Medical’s Wrapsody cell-impermeable endoprosthesis that achieved strong primary patency for hemodialysis access^{[2]Merit Medical, “Wrapsody WAVE Trial Results,” endovascular-today.com}. Angioplasty and stenting benefit from absorbable scaffolds that support vessel healing while ensuring drug delivery, such as Abbott’s Esprit BTK platform. Ablation technology progression yields predictable lesion boundaries and shrinks collateral injury, broadening oncology and pain-management indications. Consequently, the interventional radiology market size attributed to therapeutic services is projected to reach USD 25.2 billion by 2030 at segment level.

Diagnostic procedures hold a 38.23% share, providing essential imaging roadmaps for interventionists but delivering lower revenue per case. Nevertheless, innovations in cone-beam CT and AI-assisted angiography enhance diagnostic accuracy, indirectly supporting therapeutic expansion. Biopsy and drainage remain vital for oncologic staging and infection control. The enduring diagnostic foundation ensures a steady flow of patients into the therapeutic pipeline, sustaining growth momentum in the broader interventional radiology market.

By Application: Oncology Leadership Challenged By Urology Surge

Oncology remains the largest application, owning 29.43% revenue in 2024 via liver chemoembolization and tumor ablation that demonstrate superior survival outcomes compared with surgery in select patient cohorts. Device innovation—such as precision microcatheters and drug-eluting beads—widens the scope to pancreatic and renal malignancies. Yet Urology & Nephrology is scaling fastest at an 8.23% CAGR, buoyed by guideline-backed prostatic artery embolization that offers durable symptom relief for benign prostatic hyperplasia. FDA approval of ultrasound renal denervation for hypertension further expands the addressable patient base.

Cardiology interventions persist in structural heart and pulmonary embolism management, while gastroenterology cases leverage portal vein recanalization and biliary drainage to defer surgical interventions. Musculoskeletal and pain-management procedures round out emerging niches, underscoring the broadening therapeutic reach of the interventional radiology industry across diverse disease states.

By End-User: Outpatient Facilities Challenge Hospital Dominance

Hospitals control 57.98% of 2024 revenue due to intensive care capabilities and readiness for emergent complications. They remain central for multi-disciplinary tumor boards and combined surgical-interventional cases. However, Office-Based Labs (OBLs) and specialized Imaging Centers are expanding at an 8.54% CAGR, aided by lower overhead, convenient locations, and tailored workflows. The interventional radiology market size for OBLs is on track to exceed USD 9 billion by 2030 as reimbursement parity for select procedures levels the economic playing field.

Ambulatory Surgical Centers exploit simplified credentialing to adopt intricate interventions such as outpatient cerebral angiography with safety profiles comparable to inpatient settings. Health systems respond through spoke-and-hub networks that anchor complex cases in flagship hospitals while channeling routine interventions to satellite centers, preserving market reach amid the outpatient shift.

Geography Analysis

North America commanded 43.21% revenue in 2024, supported by established clinical guidelines, high device penetration, and robust R&D commitments including Siemens Healthineers’ USD 150 million facility expansion in the United States. Payment pressures loom as Medicare enacts a 2.83% fee schedule reduction and a projected 4% cut in interventional radiology reimbursements, spurring provider investment in cost-efficient outpatient capacity. Regulatory initiatives such as the FDA’s Transitional Coverage for Emerging Technologies pathway expedite market uptake for breakthrough devices, sustaining innovation flow despite fiscal tightening.

Asia-Pacific registers the fastest growth at a 6.34% CAGR, fueled by large unmet procedural needs, urban hospital build-outs, and joint ventures. Inari Medical’s partnership with 6 Dimensions Capital accelerates commercialization of thrombectomy devices in Greater China, illustrating foreign-domestic collaboration that localizes advanced therapies. Governments prioritize imaging infrastructure and physician training to curb outbound medical tourism, while public-private alliances leverage cloud platforms to scale AI tools across regional networks.

Europe maintains stable expansion anchored by tight device-safety standards and strong university hospital networks. Philips led European Patent Office filings with 594 medical technology applications in 2024, reinforcing the region’s innovation reputation. Eastern European systems allocate European Union cohesion funds to upgrade angiography labs, boosting procedure capacity. The Middle East & Africa and South America remain nascent but show accelerating adoption as training initiatives like Tanzania’s Road2IR program complete more than 1,500 procedures with high success rates^{[3]Road2IR, “Training Outcomes in Tanzania,” auntminnie.com}. Multinational OEMs tailor financing packages to penetrate these value-conscious markets, diversifying revenue streams across the global interventional radiology market.

Competitive Landscape

The landscape is moderately consolidated, with imaging conglomerates, catheter specialists, and emerging robotic firms competing on integrated ecosystems. Siemens Healthineers grew Advanced Therapies revenue by 8.0% in 2025 and secured a 10-year modernization partnership with Tower Health, reinforcing its platform approach to imaging, software, and service bundles. Philips invests heavily in AI collaboration, targeting seamless workflows from acquisition to reporting, while emphasizing helium-free MRI to lower lifecycle costs.

Strategic M&A reshapes market boundaries. Stryker’s USD 4.9 billion acquisition of Inari Medical grants immediate entry to high-growth venous thrombectomy and expands its vascular franchise. Boston Scientific broadened its liver-oncology armamentarium by acquiring Intera Oncology devices that deliver hepatic arterial infusion chemotherapy. Robotics innovators pursue niche disruption; Stereotaxis filed for FDA clearance of its EMAGIN catheter, aiming to integrate magnetic navigation with 3D imaging for endovascular procedures.

Patent portfolios remain critical moats. Philips controls 50,500 active patent rights globally, securing freedom to operate across AI, MR gradient coils, and dose-optimization algorithms. At the same time, small device firms leverage faster iteration to target specific indications, often partnering with large OEMs for commercialization scale. Competitive intensity is expected to rise as reimbursement models favor differentiated clinical outcomes that justify premium pricing, compelling all players to accelerate innovation cycles throughout the interventional radiology market.